PAOLI, Pa. and LOS ALTOS HILLS, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Sedor Pharmaceuticals, LLC (Sedor) and Los Altos Pharmaceuticals, Inc. (Los Altos) announce that Sedor has granted Los Altos an exclusive license for Captisol-enabled™ (CE) Meloxicam for the People’s Republic of China (PRC). Los Altos, located in Los Altos Hills, CA, has received exclusive development, manufacturing and commercialization rights for the People’s Republic of China and Taiwan, Hong Kong and Macau and will collaborate with Sedor on the development of CE-Meloxicam.
Sedor is currently in development with IM/IV CE-Meloxicam for the treatment of acute post-surgery, trauma and cancer pain. If approved, IM/IV CE-Meloxicam would offer an alternative to opioids and their associated side effects. Barry Frankel, Chief Business Officer and co-founder of Sedor, commented, “Following the earlier licensing of our lead development product, CE-Fosphenytoin for the treatment of status epilepticus, in the Chinese market, we are delighted to report this expansion of our licensing presence in this major territory with our second differentiated product, CE-Meloxicam. These new formulations of medicines will provide health care providers effective solutions to unmet needs of patients that improve their quality of life and clinical outcomes. We are looking forward to advancing these programs for the People’s Republic of China.”
“We are very pleased to be partnering with Sedor for this Captisol-enabled™ program. Sedor executives have three decades of expertise with biologics and pharmaceuticals, and a track record of success in bringing development-stage programs through to commercialization to benefit patients and providers,” said Zhijian Xi, Founder and CEO of Los Altos. “We look forward to bringing CE-Meloxicam to the Greater China market and offering advantages to hospitalized patients.”
About Sedor Pharmaceuticals, LLC
Sedor Pharmaceuticals, LLC identifies and acquires acute care hospital pharmaceutical assets and applies its team’s deep development, operational, manufacturing and commercialization expertise to create global clinical and economic value. The company is led by John Sedor as Chairman and an experienced team of pharmaceutical professionals with a proven track record building pharmaceutical companies and shareholder value. The company’s lead program, CE-Fosphenytoin, has been filed with the FDA for the treatment of status epilepticus offering, if approved, the potential to shorten the seizure and improve outcomes. The company’s second program, CE-Meloxicam, is preparing for Phase I development for the treatment of acute post-surgical pain and, if approved, offers the potential to replace or delay the use of IM/IV opioids. Both products were licensed from Ligand Pharmaceuticals.
CE-Fosphenytoin is available for licensing in North America, Europe, and other territories except for the Peoples Republic of China, where it has already been successfully licensed. Sedor is also in the process of seeking additional financing for pipeline development.
About Los Altos Pharmaceuticals, Inc.
Los Altos Pharmaceuticals, Inc. specializes in bringing the best pharmaceutical products to the Chinese market, and in making drugs developed in China available to the world. Los Altos’s goal is to build a leading pharmaceutical company in China that competes on the world stage. With the licensing of CE-Meloxicam to the Greater China market, we seek to bring the best standard of care of pain medication to China and benefit the largest surgical population in the world.
Forward-Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties and reflect the parties’ judgment as of the date of this release. Words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding: growth in the number of products in Sedor’s portfolio, the research and development expenditures of Sedor’s partners, including Sedor’s and Los Altos’s future revenues and other projected financial measures, and the timing and results of Sedor’s clinical trials and clinical trials to be conducted by Sedor’s partners, including Los Altos. Actual events or results may differ from Sedor’s expectations. For example, Sedor and its partners, including Los Altos, may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline. In addition, there can be no assurance that results of any clinical study will be timely, favorable or confirmed by later studies, that products under development by Sedor or its partners will receive regulatory approval, that there will be a market for the product(s) if successfully developed and approved, or that Sedor’s partners will not terminate any of its agreements or development or commercialization of any of its products. Also, Sedor and its partners, including Los Altos, may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit the ability to obtain regulatory approval. Further, unexpected adverse side effects or inadequate therapeutic efficacy of Sedor’s or its partners’ product(s) could delay or prevent regulatory approval or commercialization. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts For Business Development Inquiries, please contact
Geller Biopharm Inc. Avi Holchendler, MD avi@gellerbp.com 212-315-0600
For General Inquiries, please contact
Sedor Pharmaceuticals, LLC Christy Troiano, 610-455-2180 ctroiano@sedorpharmaceuticals.com
or Los Altos Pharmaceuticals, Incorporated Zhijian Xi, 650-353-6800 zhijianxi100@qq.com
